Exploring Three High Growth Tech Stocks For Dynamic Portfolios

ALNY Stock  USD 253.74  0.39  0.15%   
Slightly above 61% of Alnylam Pharmaceuticals' investor base is looking to short. The analysis of the overall investor sentiment regarding Alnylam Pharmaceuticals suggests that many traders are alarmed. Alnylam Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Alnylam Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
  
As global markets experience a rally driven by expectations of growth and tax reforms following recent U.S. elections, small-cap stocks like those in the Russell 2000 Index have shown significant gains, reflecting investor optimism about potential economic support measures. In this dynamic environment, identifying high-growth tech stocks that can adapt to regulatory changes and capitalize on economic trends is crucial for building robust portfolios.

Read at simplywall.st
Simply Wall St News at Macroaxis
  

Alnylam Pharmaceuticals Current Investor Sentiment

Panic Vs Confidence

39

 
Panic
 
Confidence
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Alnylam Pharmaceuticals' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Alnylam Pharmaceuticals.

Alnylam Pharmaceuticals Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Alnylam Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Alnylam Pharmaceuticals Historical Investor Sentiment

Investor biases related to Alnylam Pharmaceuticals' public news can be used to forecast risks associated with an investment in Alnylam. The trend in average sentiment can be used to explain how an investor holding Alnylam can time the market purely based on public headlines and social activities around Alnylam Pharmaceuticals. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Alnylam Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Alnylam Pharmaceuticals and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Alnylam Pharmaceuticals news discussions. The higher the estimate score, the more favorable the investor's outlook on Alnylam Pharmaceuticals.

Alnylam Pharmaceuticals Fundamental Analysis

We analyze Alnylam Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Alnylam Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Alnylam Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Working Capital

Working Capital Comparative Analysis

Alnylam Pharmaceuticals is currently under evaluation in working capital category among its peers. Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .

Alnylam Pharmaceuticals Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Alnylam Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Alnylam Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Alnylam Pharmaceuticals by comparing valuation metrics with similar companies.

Peers

Alnylam Pharmaceuticals Related Equities

APLSApellis Pharmaceuticals   4.63   
0%
100.0%
PRQRProQR Therapeutics   4.63   
0%
100.0%
HALOHalozyme Therapeutics   1.42   
0%
30.0%
DAWNDay One   1.33   
0%
28.0%
WVEWave Life   1.08   
0%
23.0%
INCYIncyte   0.87   
0%
18.0%
BMRNBiomarin Pharmaceutical   0.83   
0%
17.0%
BPMCBlueprint Medicines   0.50   
0%
10.0%
UTHRUnited Therapeutics   0.30   
0%
6.0%
KRYSKrystal Biotech   0.20   
0%
4.0%
AMLXAmylyx Pharmaceuticals   0.00   
0%
0%
RAREUltragenyx   0.00   
0%
0%
MDGLMadrigal Pharmaceuticals   0.81   
17.0%
0%
EXELExelixis   1.43   
30.0%
0%

Additional Tools for Alnylam Stock Analysis

When running Alnylam Pharmaceuticals' price analysis, check to measure Alnylam Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alnylam Pharmaceuticals is operating at the current time. Most of Alnylam Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Alnylam Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alnylam Pharmaceuticals' price. Additionally, you may evaluate how the addition of Alnylam Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.